Your browser doesn't support javascript.
loading
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.
Gaudio, E; Tarantelli, C; Kwee, I; Barassi, C; Bernasconi, E; Rinaldi, A; Ponzoni, M; Cascione, L; Targa, A; Stathis, A; Goodstal, S; Zucca, E; Bertoni, F.
Afiliação
  • Gaudio E; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona.
  • Tarantelli C; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona.
  • Kwee I; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona; Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno; Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland.
  • Barassi C; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona.
  • Bernasconi E; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona.
  • Rinaldi A; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona.
  • Ponzoni M; Unit of Lymphoid Malignancies, Department of Onco-Haematology, San Raffaele Scientific Institute, Milan, Italy.
  • Cascione L; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona; IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Targa A; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona.
  • Stathis A; IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Goodstal S; Translational and Biomarker Research, Translational Innovation Platform Oncology, EMD Serono Research and Development Institute, Billerica, USA.
  • Zucca E; IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Bertoni F; Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona; IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. Electronic address: frbertoni@mac.com.
Ann Oncol ; 27(6): 1123-1128, 2016 06.
Article em En | MEDLINE | ID: mdl-26961147
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Linfoma de Células B / Niacinamida / Classe I de Fosfatidilinositol 3-Quinases Limite: Animals / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Linfoma de Células B / Niacinamida / Classe I de Fosfatidilinositol 3-Quinases Limite: Animals / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article